Pliant Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing medicines to treat fibrosis—the scarring that makes organs like the lungs and liver stiff. Pliant's name plays on its mission: its therapies aim to make rigid, scarred tissue "pliant," or flexible again. Founded in 2015 by researchers from the University of California, San Francisco, the company targets integrins, proteins that drive the scarring process, with drug candidates for fibrotic and cancer conditions.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 13GPassive | 8.9% | 5.51M | Aug 14, 2026 |
| Daniel Schneeberger | 13GPassive | 8.9% | 5.51M | Aug 14, 2026 |
| Kenneth Griffin | 13G/APassive | 3.5% | 2.14M | Aug 14, 2026 |
| Citadel Advisors LLC | 13G/APassive | 2.3% | 1.42M | Aug 14, 2026 |
| Citadel Advisors Holdings LP | 13G/APassive | 2.3% | 1.42M | Aug 14, 2026 |
| Citadel GP LLC | 13G/APassive | 2.3% | 1.42M | Aug 14, 2026 |
| Citadel Securities Group LP | 13G/APassive | 1.2% | 725.4K | Aug 14, 2026 |
| Citadel Securities GP LLC | 13G/APassive | 1.2% | 725.4K | Aug 14, 2026 |
| Citadel Securities LLC | 13G/APassive | 1.1% | 673.1K | Aug 14, 2026 |
| Woodline Partners LP | 13G/APassive | 3.3% | 2.03M | Feb 17, 2026 |